What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Yuichiro Ohe mainly focuses on Lung cancer, Internal medicine, Oncology, Surgery and Cancer research.
His study in Lung cancer is interdisciplinary in nature, drawing from both Carcinoma, Cisplatin and Epidermal growth factor receptor.
Internal medicine and Gastroenterology are commonly linked in his work.
His Oncology study integrates concerns from other disciplines, such as Prospective cohort study, Adverse effect, Pharmacology and Vandetanib.
His Surgery research focuses on subjects like Hazard ratio, which are linked to Icotinib.
His Cancer research research incorporates elements of Cancer cell, Transfection, Immunology, non-small cell lung cancer and PTEN.
His most cited work include:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (6022 citations)
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (1436 citations)
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer (1243 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
His research in Internal medicine focuses on subjects like Gastroenterology, which are connected to Toxicity.
The Oncology study combines topics in areas such as Nivolumab, Phases of clinical research and Docetaxel.
His Lung cancer study combines topics from a wide range of disciplines, such as Carboplatin, Cancer research, Neutropenia and Epidermal growth factor receptor.
His Chemotherapy research is multidisciplinary, relying on both Regimen and Irinotecan.
His Surgery study typically links adjacent topics like Hazard ratio.
He most often published in these fields:
- Internal medicine (64.35%)
- Oncology (46.53%)
- Lung cancer (41.54%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.35%)
- Oncology (46.53%)
- Lung cancer (41.54%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Lung cancer, Nivolumab and Non small cell.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
His work deals with themes such as Cancer, Clinical trial and Chemotherapy, which intersect with Oncology.
As part of the same scientific family, Yuichiro Ohe usually focuses on Lung cancer, concentrating on Lung and intersecting with Biopsy.
His work in Non small cell addresses issues such as Cancer research, which are connected to fields such as Kinase and Mutation.
His research investigates the connection with Osimertinib and areas like Confidence interval which intersect with concerns in Gefitinib and Erlotinib.
Between 2018 and 2021, his most popular works were:
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC (359 citations)
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (71 citations)
- Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). (67 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Lung cancer, Oncology, Nivolumab and Gastroenterology.
His study in Clinical endpoint, Adverse effect, Hazard ratio, Osimertinib and Interstitial lung disease are all subfields of Internal medicine.
The concepts of his Lung cancer study are interwoven with issues in Neutropenia, Clinical trial and Survival analysis.
His Neutropenia study incorporates themes from Entrectinib and Chemoradiotherapy.
His work on Crizotinib as part of general Oncology research is frequently linked to Response Evaluation Criteria in Solid Tumors, bridging the gap between disciplines.
His Gastroenterology research integrates issues from Progressive disease, Toxicity, Phases of clinical research, Tolerability and Nausea.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
